SU1644

SU1644 is an experimental small-molecule inhibitor of IκB kinase alpha (IKKα), developed initially at the University of Strathclyde as part of a program to create first-in-class selective IKKα inhibitors for cancer therapy, particularly castration-resistant prostate cancer. By selectively targeting IKKα, SU1644 is intended to modulate NF-κB signaling pathways implicated in tumor progression, survival, and resistance to therapy, with the goal of providing a novel targeted treatment option in oncology. Public information indicates that SU1644 remains at the research and preclinical development stage, without reported clinical trial use or marketing authorization.